

marcia Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7199996/publications.pdf>

Version: 2024-02-01

66
papers

3,302
citations

257450

24
h-index

155660

55
g-index

68
all docs

68
docs citations

68
times ranked

5588
citing authors

#	ARTICLE	IF	CITATIONS
1	Differential Expression of RAD51AP1 in Ovarian Cancer: Effects of siRNA In Vitro. <i>Journal of Personalized Medicine</i> , 2022, 12, 201.	2.5	1
2	In Silico Study to Predict the Structural and Functional Consequences of SNPs on Biomarkers of Ovarian Cancer (OC) and BPA Exposure-Associated OC. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1725.	4.1	4
3	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). <i>Journal of Clinical Oncology</i> , 2022, 40, 2468-2478.	1.6	22
4	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 919-930.	10.7	11
5	Objective responses to first-line neoadjuvant carboplatin+paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 277-288.	10.7	34
6	Imaging modality and frequency in surveillance of stage I seminoma testicular cancer: Results from a randomized, phase III, factorial trial (TRISST).. <i>Journal of Clinical Oncology</i> , 2021, 39, 374-374.	1.6	9
7	COVID-19 and SARS-CoV-2 host cell entry mediators: Expression profiling of TMRSS4 in health and disease. <i>International Journal of Molecular Medicine</i> , 2021, 47, .	4.0	23
8	Identification of Potential Bisphenol A (BPA) Exposure Biomarkers in Ovarian Cancer. <i>Journal of Clinical Medicine</i> , 2021, 10, 1979.	2.4	11
9	A pancancer overview of FBN1, asprosin and its cognate receptor OR4M1 with detailed expression profiling in ovarian cancer. <i>Oncology Letters</i> , 2021, 22, 650.	1.8	15
10	Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status. <i>Cells</i> , 2021, 10, 2434.	4.1	2
11	Circulating tumour cells and circulating cell-free DNA in patients with lung cancer: a comparison between thoracotomy and video-assisted thoracoscopic surgery. <i>BMJ Open Respiratory Research</i> , 2021, 8, e000917.	3.0	1
12	Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours. <i>British Journal of Cancer</i> , 2020, 122, 483-490.	6.4	8
13	Co-expression of peripheral olfactory receptors with SARS-CoV-2 infection mediators: Potential implications beyond loss of smell as a COVID-19 symptom. <i>International Journal of Molecular Medicine</i> , 2020, 46, 949-956.	4.0	34
14	Survival Outcomes After High-dose Chemotherapy and Stem Cell Transplantation in the Salvage Setting for Relapsed or Refractory Germ Cell Cancers. <i>In Vivo</i> , 2020, 34, 3675-3679.	1.3	1
15	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2020, 33, 287-297.	1.1	10
16	Identification of Cancer-Associated Circulating Cells in Anal Cancer Patients. <i>Cancers</i> , 2020, 12, 2229.	3.7	6
17	H2A Histone Family Member X (H2AX) Is Upregulated in Ovarian Cancer and Demonstrates Utility as a Prognostic Biomarker in Terms of Overall Survival. <i>Journal of Clinical Medicine</i> , 2020, 9, 2844.	2.4	10
18	Real world outcomes in platinum sensitive relapsed ovarian, fallopian tube, or peritoneal cancer treated in routine clinical practice in the United Kingdom prior to poly-ADP ribose polymerase inhibitors. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 1026-1033.	2.5	3

#	ARTICLE	IF	CITATIONS
19	Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 969-977.	10.7	23
20	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4767-4776.	7.0	68
21	British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 252, 502-525.	1.1	36
22	Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial. <i>Gynecologic Oncology</i> , 2020, 156, 545-551.	1.4	14
23	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 398-411.	10.7	152
24	Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study. <i>International Journal of Gynecological Cancer</i> , 2020, 30, 213-220.	2.5	22
25	Neuropilin-1 as a new potential SARS-CoV-2 infection mediator implicated in the neurologic features and central nervous system involvement of COVID-19. <i>Molecular Medicine Reports</i> , 2020, 22, 4221-4226.	2.4	102
26	Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry. <i>International Journal of Molecular Medicine</i> , 2019, 43, 47-56.	4.0	24
27	Reply to "Denominator-Based Studies Need Full Disclosure of the Origins of Patients Treated". <i>Annals of Surgical Oncology</i> , 2019, 26, 874-875.	1.5	0
28	Detection of Abundant Non-Haematopoietic Circulating Cancer-Related Cells in Patients with Advanced Epithelial Ovarian Cancer. <i>Cells</i> , 2019, 8, 732.	4.1	5
29	Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 542.	2.8	19
30	Maximal-Effort Cytoreductive Surgery for Ovarian Cancer Patients with a High Tumor Burden: Variations in Practice and Impact on Outcome. <i>Annals of Surgical Oncology</i> , 2019, 26, 2943-2951.	1.5	54
31	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , 2019, 293, 374-383.	7.3	25
32	Kinase Inhibitors and Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1357.	3.7	20
33	Somatic Transformation in Metastatic Testicular Germ Cell Tumours " A Different Disease Entity. <i>Anticancer Research</i> , 2019, 39, 4911-4916.	1.1	9
34	Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial " ANZGOG 0903. <i>Gynecologic Oncology</i> , 2019, 154, 29-37.	1.4	35
35	Liquid Biopsies in Lung Cancer: Four Emerging Technologies and Potential Clinical Applications. <i>Cancers</i> , 2019, 11, 331.	3.7	13
36	Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GICG phase 3 randomised controlled trial. <i>Lancet</i> , The, 2019, 394, 2084-2095.	13.7	142

#	ARTICLE	IF	CITATIONS
37	Phase IB Dose Escalation and Expansion Study of AKT Inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-resistant Ovarian Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 1472-1478.	7.0	38
38	A Qualitative Analysis of the Impact of Carboplatin AUC 10 on Physical, Work Functioning and Bone Marrow Toxicity Among Seminoma Patients – A Single-centre Experience. <i>In Vivo</i> , 2019, 33, 233-237.	1.3	6
39	Identification of cancer biomarkers of prognostic value using specific gene regulatory networks (GRN): a novel role of RAD51AP1 for ovarian and lung cancers. <i>Carcinogenesis</i> , 2018, 39, 407-417.	2.8	38
40	Prognostic value of the DNA integrity index in patients with malignant lung tumors. <i>Oncotarget</i> , 2018, 9, 21281-21288.	1.8	16
41	Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. <i>Lancet Oncology</i> , The, 2018, 19, 1680-1687.	10.7	187
42	Copy number signatures and mutational processes in ovarian carcinoma. <i>Nature Genetics</i> , 2018, 50, 1262-1270.	21.4	320
43	Do Not Give Up. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1060-1062.	2.5	1
44	British Gynaecological Cancer Society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 123-139.	1.1	64
45	Audit of CA125 Follow-Up After First-Line Therapy for Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1118-1122.	2.5	7
46	Surgery for Recurrent Uterine Cancer: Surgical Outcomes and Implications for Survival – A Case Series. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 759-767.	2.5	4
47	ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer. <i>European Journal of Cancer</i> , 2017, 70, 111-121.	2.8	70
48	PARP inhibitors and chemoradiation for rectal cancer. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 389-390.	8.1	0
49	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	10.7	293
50	We Have the Tools: It's Time to Use Them Correctly!. <i>Journal of Clinical Oncology</i> , 2017, 35, 1494-1495.	1.6	1
51	An Association of Cancer Physicians –™ strategy for improving services and outcomes for cancer patients. <i>Ecancermedalscience</i> , 2016, 10, 608.	1.1	5
52	Background and Current Treatment of Squamous Cell Carcinoma of the Anus. <i>Oncology and Therapy</i> , 2016, 4, 135-172.	2.6	18
53	The pro-social neurohormone oxytocin reverses the actions of the stress hormone cortisol in human ovarian carcinoma cells in vitro. <i>International Journal of Oncology</i> , 2016, 48, 1805-1814.	3.3	20
54	Differential effects of rapalogues, dual kinase inhibitors on human ovarian carcinoma cells in vitro. <i>International Journal of Oncology</i> , 2016, 49, 133-143.	3.3	12

#	ARTICLE	IF	CITATIONS
55	Maximal effort cytoreductive surgery for disseminated ovarian cancer in a UK setting: challenges and possibilities. Archives of Gynecology and Obstetrics, 2016, 294, 607-614.	1.7	27
56	An update on PARP inhibitors for the treatment of cancer. OncoTargets and Therapy, 2015, 8, 519.	2.0	72
57	A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol. BMC Cancer, 2014, 14, 983.	2.6	10
58	Randomized Phase III Study of Erlotinib Versus Observation in Patients With No Evidence of Disease Progression After First-Line Platin-Based Chemotherapy for Ovarian Carcinoma: A European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup Study. Journal of Clinical Oncology, 2014, 32, 320-326.	1.6	99
59	Targeted anti-vascular therapies for ovarian cancer: current evidence. British Journal of Cancer, 2013, 108, 250-258.	6.4	64
60	Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib. OncoTargets and Therapy, 2013, 6, 1197.	2.0	12
61	Recurrent Ovarian Cancer: When and How to Treat. Current Oncology Reports, 2011, 13, 459-471.	4.0	28
62	An Unusual Case of Sex Cord Tumor With Annular Tubules With Malignant Transformation in a Patient With Peutz-Jeghers Syndrome. International Journal of Gynecological Pathology, 2010, 29, 27-32.	1.4	26
63	Longer-Term Assessment of Trastuzumab-Related Cardiac Adverse Events in the Herceptin Adjuvant (HERA) Trial. Journal of Clinical Oncology, 2010, 28, 3422-3428.	1.6	228
64	A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 2006, 58, 809-815.	2.3	16
65	Reducing morbidity from insertion of chest drains. BMJ: British Medical Journal, 1997, 315, 313-313.	2.3	6
66	Genetic Alterations of Cyclins, Cyclin-Dependent Kinases, and Cdk Inhibitors in Human Cancer. Advances in Cancer Research, 1996, 68, 67-108.	5.0	646